{"id":2811,"date":"2021-02-01T12:03:00","date_gmt":"2021-02-01T11:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2021\/leserbrief-ivermectin-zur-behandlung-von-covid-19"},"modified":"2021-02-01T12:03:00","modified_gmt":"2021-02-01T11:03:00","slug":"leserbrief-ivermectin-zur-behandlung-von-covid-19","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2021\/leserbrief-ivermectin-zur-behandlung-von-covid-19","title":{"rendered":"Leserbrief: Ivermectin zur Behandlung von COVID-19?"},"content":{"rendered":"<p>Dr. W. aus K. schreibt: >> Ich bin Internist und Geriater. Viele meiner Patienten haben ein sehr hohes Risiko f\u00fcr schwere Verl\u00e4ufe bei COVID-19. Seit L\u00e4ngerem besch\u00e4ftigt mich das MATH+ Behandlungsprotokoll der Front Line COVID-19 Critical Care Alliance (FLCCCA). Krankenh\u00e4user in den USA, die das Protokoll anwenden, erzielen damit angeblich eine Letalit\u00e4t von nur 5-6% [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr. W. aus K. schreibt: >> Ich bin Internist und Geriater. Viele meiner Patienten haben ein sehr hohes Risiko f\u00fcr schwere Verl\u00e4ufe bei COVID-19. Seit L\u00e4ngerem besch\u00e4ftigt mich das MATH+ Behandlungsprotokoll der Front Line COVID-19 Critical Care Alliance (FLCCCA). Krankenh\u00e4user in den USA, die das Protokoll anwenden, erzielen damit angeblich eine Letalit\u00e4t von nur 5-6% [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[5340,5339,825,5338],"class_list":["post-2811","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-coronavirus","tag-covid-19","tag-ivermectin","tag-sars-cov-2"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2811"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2811\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}